CA2463404A1 - Fragements of heat shock proteins and their use - Google Patents

Fragements of heat shock proteins and their use Download PDF

Info

Publication number
CA2463404A1
CA2463404A1 CA002463404A CA2463404A CA2463404A1 CA 2463404 A1 CA2463404 A1 CA 2463404A1 CA 002463404 A CA002463404 A CA 002463404A CA 2463404 A CA2463404 A CA 2463404A CA 2463404 A1 CA2463404 A1 CA 2463404A1
Authority
CA
Canada
Prior art keywords
heat shock
shock protein
protein fragment
fragment
hsp70
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002463404A
Other languages
English (en)
French (fr)
Inventor
Thomas Lehner
Charles George Kelly
Mahavir Singh
Yufei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2463404A1 publication Critical patent/CA2463404A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002463404A 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use Abandoned CA2463404A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0123756.9 2001-10-03
GBGB0123756.9A GB0123756D0 (en) 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1
PCT/GB2002/004475 WO2003029289A2 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use

Publications (1)

Publication Number Publication Date
CA2463404A1 true CA2463404A1 (en) 2003-04-10

Family

ID=9923176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002463404A Abandoned CA2463404A1 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use

Country Status (7)

Country Link
US (1) US20060264609A1 (enExample)
EP (1) EP1434794A2 (enExample)
JP (1) JP2005512518A (enExample)
AU (1) AU2002329450A1 (enExample)
CA (1) CA2463404A1 (enExample)
GB (1) GB0123756D0 (enExample)
WO (1) WO2003029289A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151049A (zh) * 2004-06-15 2008-03-26 纽约血液中心有限公司 旋盘尾丝虫的天然产物的佐剂和免疫加强性能
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
CN101801402B (zh) * 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 炎性疾病和自身免疫疾病的治疗和预防
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
US20170260286A1 (en) * 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018049118A1 (en) * 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
AU2021357131A1 (en) * 2020-10-09 2023-05-25 Zeria Pharmaceutical Co., Ltd. Novel use of mycobacterium tuberculosis extract
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777890B1 (fr) * 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
GB9930443D0 (en) * 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
WO2002061113A2 (en) * 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation

Also Published As

Publication number Publication date
JP2005512518A (ja) 2005-05-12
WO2003029289A3 (en) 2003-08-28
AU2002329450A1 (en) 2003-04-14
GB0123756D0 (en) 2001-11-21
EP1434794A2 (en) 2004-07-07
US20060264609A1 (en) 2006-11-23
WO2003029289A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
KR102653758B1 (ko) 인터류킨-2/인터류킨-2 수용체 알파 융합 단백질 및 사용 방법
US20200354412A1 (en) Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US5747024A (en) Vaccine adjuvant comprising interleukin-15
KR20140128977A (ko) Cd4+ t-세포 반응의 증강을 위한 변형된 에피토프
JP2010059172A (ja) 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
CZ298347B6 (cs) Fúzní protein z rodiny MAGE, kódová sekvence nukleové kyseliny, vektor, hostitelská bunka, vakcina a použití fúzního proteinu pro výrobu vakciny
US6537552B1 (en) Vaccine adjuvant
US20060264609A1 (en) Use of heat shock proteins
Mitsui et al. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity
JP2003519668A (ja) 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
CN101096680A (zh) 一种dna疫苗真核表达载体及其在制备基因疫苗中的应用
Anna et al. A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity
CN100467063C (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
Namkoong et al. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11
WO1998008947A1 (en) Enhancement of dna immunization through the use of cytokines
AU2005203772B2 (en) Fusion protein for inhibiting cancer and uses thereof
WO2017177908A1 (zh) Pd-l1和pd-l2重组蛋白及其用途
EP3517542B1 (en) Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide
WO2017177907A1 (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
WO2005051414A1 (en) Use of c4bp core region as a cd40 agonist
Yoshida et al. Protective CTL response is induced in the absence of CD4+ T cells and IFN-γ by gene gun DNA vaccination with a minigene encoding a CTL epitope of Listeria monocytogenes
Liu et al. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356–364 epitope fusion protein
US20260008821A1 (en) Modified hiv envelope antigens and method of use thereof
EP1757615B1 (en) Fusion protein for inhibiting cervical cancer
Raz Introduction: gene vaccination, current concepts and future directions

Legal Events

Date Code Title Description
FZDE Discontinued